Phase I/II Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Summary
The purpose of this phase I/IIa study is to determine the safety and efficacy of FF-10502-01 in patients with advanced solid tumors and lymphomas. Phase II will consist of 2 cohorts: Cohort 1 will include patients with Pancreatic Cancer. Cohort 2 will include patients with another tumor type enrolled in the Phase I dose-escalation phase who have demonstrated Clinical Benefit by Week 16.
General Information
NCT#: NCT02661542
Study ID: FF-10502-01
Trial Phase: Phase I/II
Trial Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.
Therapies Used in This Trial: FF-10502-01